Italy -
Italian -
AIFA (Agenzia Italiana del Farmaco)
isosorbide mononitrato ahcl
accord healthcare limited - isosorbide mononitrato - isosorbide mononitrato
European Union -
Italian -
EMA (European Medicines Agency)
tysabri
biogen netherlands b.v. - natalizumab - sclerosi multipla - immunosoppressori selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
European Union -
Italian -
EMA (European Medicines Agency)
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
Italy -
Italian -
AIFA (Agenzia Italiana del Farmaco)
prohance
bracco imaging s.p.a. - gadoteridolo - gadoteridolo
Italy -
Italian -
AIFA (Agenzia Italiana del Farmaco)
ritalin
infectopharm arzneimittel und consilium gmbh - metilfenidato - metilfenidato
European Union -
Italian -
EMA (European Medicines Agency)
ozurdex
abbvie deutschland gmbh & co. kg - desametasone - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex è indicato per il trattamento di pazienti adulti affetti da edema maculare, in seguito a uno filiale di retina-occlusione della vena (brvo) o centrale della retina-occlusione della vena (crvo). ozurdex è indicato per il trattamento di pazienti adulti affetti da infiammazione del segmento posteriore dell'occhio, che si presenta come uveite noninfectious. ozurdex è indicato per il trattamento di pazienti adulti con disabilità visiva a causa di edema maculare diabetico (dme) che sono pseudophakic o che sono considerati non sufficientemente reattivo, o non idoneo non la terapia con corticosteroidi.
Italy -
Italian -
AIFA (Agenzia Italiana del Farmaco)
ifyltan
g.l. pharma gmbh - fentanil - fentanil
Switzerland -
Italian -
Swissmedic (Swiss Agency for Therapeutic Products)
attentin 5 mg,tabletten attentin 5 mg,tabletten
salmon pharma gmbh - dexamfetaminum - attentin 5 mg,tabletten - dexamfetamini sulfas 5 mg corresp. dexamfetaminum 3.67 mg, isomaltum 147.5 mg, crospovidonum, magnesii stearas, pro compresso. - adhs - synthetika
Switzerland -
Italian -
Swissmedic (Swiss Agency for Therapeutic Products)
attentin 10 mg,tabletten attentin 10 mg,tabletten
salmon pharma gmbh - dexamfetaminum - attentin 10 mg,tabletten - dexamfetamini sulfas 10 mg corresp. dexamfetaminum 7.34 mg, isomaltum 147.7 mg, e 172 (flavum), magnesii stearas, pro compresso. - adhs - synthetika